Understand the source comparison
Is SS-LUP-332 Safe? Side Effects Comparison
SS-LUP-332 ERRα/γ agonist. Forces mitochondrial shift to fat oxidation Fatigue (20–25%), GI disturbance (12–15%), transient enzyme elevation (15–20%) Transient AST/ALT increase, resolves in 10–14 days, no structural damage Moderate. Adaptation period noticeabl
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-LUP-332
- ERRα/γ agonist. Forces mitochondrial shift to fat oxidation
- Fatigue (20–25%), GI disturbance (12–15%), transient enzyme elevation (15–20%)
- Transient AST/ALT increase, resolves in 10–14 days, no structural damage
- Moderate. Adaptation period noticeable but manageable with controlled dosing
- Safe with predictable metabolic transition effects; not a toxicity concern but requires subject education on expected adaptation responses
- DNP (2,4-Dinitrophenol)
- Mitochondrial uncoupler. Disrupts ATP synthesis
- Hyperthermia (100%), tachycardia (>80%), severe sweating, neuropathy risk
- Dose-dependent hepatotoxicity, potential for fatal overdose
- Poor. Dangerous at therapeutic doses, zero margin for error
- Unsafe. Narrow therapeutic window, uncontrollable thermogenesis, banned in most jurisdictions
- GW501516 (Cardarine)
- PPARδ agonist. Increases fatty acid oxidation
- Minimal acute responses, long-term cancer risk in rodent models at high doses
- No documented hepatic toxicity in short-term use
- Excellent. Well-tolerated acutely
- Questionable long-term safety; carcinogenicity observed in animal studies limits research application
- Berberine
- AMPK activator. Improves insulin sensitivity, modest fat oxidation
- GI distress (25–40%), cramping, diarrhoea at >1.5g/day
- Minimal impact at standard doses
- Moderate. GI side effects dose-limiting for some users
- Safe and well-tolerated at ≤1.5g/day; effects are modest compared to synthetic ERR agonists
- Metformin
- AMPK activator, complex I inhibitor. Reduces hepatic glucose output
- GI distress (25–30%), lactic acidosis risk (rare), vitamin B12 depletion (long-term)
- Minimal hepatic impact, contraindicated in hepatic impairment
- Moderate. GI effects common in first 2 weeks
- Safe for glucose management; metabolic effects are indirect and less pronounced than direct mitochondrial modulators
- This comparison underscores a critical point: SS-LUP-332 sits in a unique category. It's not an uncoupler like DNP (which generates heat as a waste byproduct and carries extreme toxicity risk), nor is it a mild insulin sensitiser like berberine. It's a targeted nuclear receptor agonist that forces a specific metabolic programme. Fat oxidation over glycolysis. Which means the body has to adapt structurally and functionally to maintain homeostasis.